These data suggest that using spectrin or laminin to normalise dystrophin intensity values will lead to an underestimation of the levels of dystrophin at the sarcolemma in dystrophinopathies. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.